Skip to main content
SpringerLink
Log in

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

  • Short Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Aim: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (ASA404), a low molecular weight antivascular drug currently in clinical trial, acts both directly on the tumour vascular endothelium and indirectly through the induction of inflammatory cytokines and other vasoactive molecules from macrophages and other host cells. We wished to determine whether co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) could modulate the antivascular effects of DMXAA in mice. Methods: The effects of diclofenac, salicylate, ibuprofen, celecoxib and rofecoxib on the antitumour response to DMXAA were compared using growth delay assays of Colon 38 adenocarcinomas in C57Bl mice. Concentrations of DMXAA in mice were measured by high performance liquid chromatography. Results: Administration of DMXAA alone (25 mg/kg i.p.) or of NSAIDs alone induced small tumour growth delays from 2 to 7 days. Co-administration of each of the NSAIDs augmented DMXAA effects with tumour growth delays from 4.5 to >20 days. The possibility of a pharmacokinetic interaction was investigated using diclofenac and it was found that diclofenac did not affect DMXAA pharmacokinetics. Conclusions: NSAIDs increase the antitumour activity of DMXAA in a murine tumour model. The effects are consistent with hypothesis that NSAIDs antagonises some of the protective effects of prostaglandins released in response to vascular injury. Co-administration of NSAIDs with DMXAA might be considered as a possible strategy for use in combination cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435 doi:10.1038/nrc1628

    Article  CAS  PubMed  Google Scholar 

  2. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143–148 doi:10.1007/BF00689199

    Article  CAS  PubMed  Google Scholar 

  3. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141–148 doi:10.1016/S1470–2045(03)01018–0

    Article  CAS  PubMed  Google Scholar 

  4. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86:1937–1942 doi:10.1038/sj.bjc.6600368

    Article  CAS  PubMed  Google Scholar 

  5. Ching LM, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90:906–910 doi:10.1038/sj.bjc.6601606

    Article  CAS  PubMed  Google Scholar 

  6. Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shut-down induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA); increased tumor vascular permeability. Int J Cancer 116:322–326 doi:10.1002/ijc.21005

    Article  CAS  PubMed  Google Scholar 

  7. McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M et al (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12:1776–1784 doi:10.1158/1078–0432.CCR-05–1939

    Article  CAS  PubMed  Google Scholar 

  8. McKeage MJ (2008) The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 17:23–29 doi:10.1517/13543784.17.1.23

    Article  CAS  PubMed  Google Scholar 

  9. Sanborn R, Blanke CD (2005) Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust? Semin Oncol 32:69–75 doi:10.1053/j.seminoncol.2004.09.035

    Article  CAS  PubMed  Google Scholar 

  10. Pereg D, Lishner M (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 258:115–123 doi:10.1111/j.1365–2796.2005.01519.x

    Article  CAS  PubMed  Google Scholar 

  11. Yang H, Majno P, Morel P, Toso C, Triponez F, Oberholzer J et al (2002) Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation. Microvasc Res 64:94–103 doi:10.1006/mvre.2002.2404

    Article  CAS  PubMed  Google Scholar 

  12. Ching LM, Joseph WR, Baguley BC (1992) Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid. Biochem Pharmacol 44:192–195 doi:10.1016/0006–2952(92)90058-Q

    Article  CAS  PubMed  Google Scholar 

  13. Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW et al (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6- dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 46:135–141 doi:10.1007/s002800000131

    Article  CAS  PubMed  Google Scholar 

  14. Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM (2001) In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemother Pharmacol 47:319–326 doi:10.1007/s002800000249

    Article  CAS  PubMed  Google Scholar 

  15. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72:339–343

    CAS  PubMed  Google Scholar 

  16. Zhao L, Kestell P, Philpott M, Ching LM, Zhuang L, Baguley BC (2001) Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 47:491–497 doi:10.1007/s002800000267

    Article  CAS  PubMed  Google Scholar 

  17. Baguley BC, Wilson WR (2002) Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2:593–603 doi:10.1586/14737140.2.5.593

    Article  CAS  PubMed  Google Scholar 

  18. Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT (2003) Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 63:7584–7590

    CAS  PubMed  Google Scholar 

  19. Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323–328

    CAS  PubMed  Google Scholar 

  20. Ferrario A, Fisher AM, Rucker N, Gomer CJ (2005) Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 20:9473–9478 doi:10.1158/0008–5472.CAN-05–1659

    Article  Google Scholar 

  21. Naisbitt DJ, Sanderson LS, Meng X, Stachulski AV, Clarke SE, Park BK (2007) Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 168:45–50 doi:10.1016/j.toxlet.2006.10.014

    Article  CAS  PubMed  Google Scholar 

  22. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83:1136–1144 doi:10.1189/jlb.0907611

    Article  CAS  PubMed  Google Scholar 

  23. Thomsen LL, Ching LM, Zhuang L, Gavin JB, Baguley BC (1991) Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 51:77–81

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Auckland Cancer Society.

Author information

Authors and Affiliations

  1. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

    L.-C. Steve Wang, Lai-Ming Ching, Philip Kestell, Rachel Sutherland, Li Zhuang & Bruce C. Baguley

  2. Department of Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

    James W. Paxton

Authors
  1. L.-C. Steve Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lai-Ming Ching
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James W. Paxton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip Kestell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachel Sutherland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bruce C. Baguley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce C. Baguley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, LC.S., Ching, LM., Paxton, J.W. et al. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. Invest New Drugs 27, 280–284 (2009). https://doi.org/10.1007/s10637-008-9167-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-008-9167-7

Keywords

Search

Navigation